Results from Phase 2 Trial of Stem-Cell Treatment for Amyotrophic Lateral Sclerosis to Be Presented at American Academy of Neurology 2018

Wednesday, February 07, 2018 | Neuromuscular


Brainstorm Cell Therapeutics Inc. announced that they will present results from the NurOwn phase 2 randomized, double-blind, placebo-controlled study, showing ALSFRS-R subgroup analyses and micro-RNA biomarker data, at the American Academy of Neurology (AAN) Annual Meeting, to take place April 21-27th in Los Angeles, California.

The data will be presented in platform sessions including:

"NurOwn® Phase 2 ALS Trial: ALSFRS-R Improvement is Reflected in Subscale Domains"

Session S38:Best of Session: Clinical Trial Updates in Neuromuscular Disorders on April 26, 2018. Presented by Merit E. Cudkowicz MD, Chief Neurology Service, Director Amyotrophic Lateral Sclerosis Clinic, Co-Director Neuromuscular Division, Massachusetts General Hospital.

"Modulation of CSF miRNAs in ALS phase 2 study participants treated with MSC-NTF cells (NurOwn®). Session S25: Advances in Amyotrophic Lateral Sclerosis on April 24, 2018. Presented by Ralph Z. Kern MD, MHSc, Chief Operating and Medical Officer, BrainStorm Cell Therapeutics.

"Our Phase 2 placebo-controlled trial demonstrated promising clinical activity for NurOwn® in ALS, and the subgroup analyses confirm that ALSFRS-R subdomains contribute to this treatment effect. The CSF biomarker data confirms that micro-RNA released by NurOwn® may contribute to its therapeutic effect in ALS", said Ralph Kern MD, BrainStorm's Chief Operating Officer and Chief Medical Officer.

"We are pleased to have these scientific abstracts accepted at the prestigious AAN Annual Meeting, which is the largest North American Neurology conference. We are committed to continuing to understand the value that NurOwn brings to ALS through innovative clinical and scientific evaluation, and to advance the phase 3 pivotal study to bring a meaningful solution to ALS patients," commented BrainStorm's CEO Chaim Lebovits.

Next Story

Comments

You must be logged in to leave a comment.